Research Article

Polymorphisms in CRHR1 and the serotonin transporter loci: Gene × Gene × Environment interactions on depressive symptoms†‡

  1. Kerry J. Ressler1,2,3,*,
  2. Bekh Bradley1,4,
  3. Kristina B. Mercer3,5,
  4. Todd C. Deveau1,
  5. Alicia K. Smith1,
  6. Charles F. Gillespie1,
  7. Charles B. Nemeroff1,
  8. Joseph F. Cubells1,5,
  9. Elisabeth B. Binder1,5,6

Article first published online: 22 DEC 2009

DOI: 10.1002/ajmg.b.31052

Issue

American Journal of Medical Genetics Part B: Neuropsychiatric Genetics

American Journal of Medical Genetics Part B: Neuropsychiatric Genetics

Volume 153B, Issue 3, pages 812–824, April 2010

Additional Information

How to Cite

Ressler, K. J., Bradley, B., Mercer, K. B., Deveau, T. C., Smith, A. K., Gillespie, C. F., Nemeroff, C. B., Cubells, J. F. and Binder, E. B. (2010), Polymorphisms in CRHR1 and the serotonin transporter loci: Gene × Gene × Environment interactions on depressive symptoms. Am. J. Med. Genet., 153B: 812–824. doi: 10.1002/ajmg.b.31052

Author Information

  1. 1

    Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, Georgia

  2. 2

    Yerkes National Primate Research Center, Atlanta, Georgia

  3. 3

    Howard Hughes Medical Institute, Chevy Chase, Maryland

  4. 4

    Atlanta VA Medical Center, Decatur, Georgia

  5. 5

    Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia

  6. 6

    Max-Planck Institute of Psychiatry, Munich, Germany

*Investigator, Howard Hughes Medical Institute; Associate Professor, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 954 Gatewood Drive, Atlanta, GA 30329.

  1. †

    Financial Disclosure Statement: There were no commercial sponsors or commercial relationships related to the current work. All additional past and present financial ties of the investigators are disclosed herein. Dr. Binder receives grant support or has received awards from NARSAD, the Doris Duke Foundation, and NIMH. Dr. Bradley receives grant support or has received awards from AFSP and the American Psychoanalytic Association Psychoanalytic Research Fund. Dr. Gillespie receives grant support or has received awards from APIRE, NARSAD, NIDA, and NIMH. Dr. Ressler has received awards and/or funding support related to other studies from Lundbeck, Burroughs Wellcome Foundation, Pfizer, NARSAD, NIMH, NIDA, and has a consulting agreement with Tikvah Therapeutics for NMDA-based therapeutics. In the past, Dr. Nemeroff consulted to, served on the Scientific Advisory Board and/or Board of Directors, has been a grant recipient, and/or owned equity in one or more of the following: Abbott Laboratories, Acadia Pharmaceuticals, American Foundation for Suicide Prevention (AFSP), American Psychiatric Institute for Research and Educations (APIRE), AstraZeneca, BMC-JR LLC, Bristol-Myers-Squibb, CeNeRx, Corcept, Cypress Biosciences, Cyberonics, Eli Lilly, Forest Laboratories, George West Mental Health Foundation, GlaxoSmithKline, i3 DLN, Janssen Pharmaceutica, Lundbeck, National Alliance for Research on Schizophrenia and Depression (NARSAD), Neuronetics, NIMH, NFMH, NovaDel Pharma, Otsuka, Pfizer Pharmaceuticals, Quintiles, Reevax, UCB Pharma, Wyeth-Ayerst. Currently, Dr. Nemeroff serves on the Scientific Advisory Board for Astra-Zeneca, Johnson & Johnson, Pharma Neuroboost, and NARSAD. He serves on the Board of Directors of AFSP, NovaDel Pharmaceuticals, Mt. Cook Pharma, Inc., and the George West Mental Health Foundation. He owns equity in CeNeRx and Reevax. He owns stock or stock options in Corcept and NovaDel. Dr. Smith has received an award from AFSP and grant support from Schering-Plough Pharmaceuticals. Dr. Ressler and Dr. Binder had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. None of the above funding agencies had any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

  2. ‡

    How to Cite this Article: Ressler KJ, Bradley B, Mercer KB, Deveau TC, Smith AK, Gillespie CF, Nemeroff CB, Cubells JF, Binder EB. 2010. Polymorphisms in CRHR1 and the Serotonin Transporter Loci: Gene × Gene × Environment Interactions on Depressive Symptoms. Am J Med Genet Part B 153B:812–824.

Publication History

  1. Issue published online: 19 MAR 2010
  2. Article first published online: 22 DEC 2009
  3. Manuscript Accepted: 21 OCT 2009
  4. Manuscript Received: 18 AUG 2009

Funded by

  • National Institutes of Mental Health. Grant Numbers: MH071537, MH069884, MH082256
  • National Institute of Drug Abuse. Grant Number: DA015766
  • Emory and Grady Memorial Hospital General Clinical Research Center
  • NIH National Centers for Research Resources. Grant Number: M01 RR00039
  • Doris Duke Foundation
  • Burroughs Wellcome Fund

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (354K)

Options for accessing this content:

  • If you have access to this content through a society membership, please first log in to your society website.
  • If you would like institutional access to this content, please recommend the title to your librarian.
  • Login via Athens http://onlinelibrary.wiley.com/athens or other institutional login options http://onlinelibrary.wiley.com/login-options .
  • You can purchase online access to this Article for a 24-hour period (price varies by title)
    • If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
    • New Users: Please register, then proceed to purchase the article.

Please register to:

  • Save publications, articles and searches
  • Get email alerts
  • Get all the benefits mentioned below!

Register now >

View Full Article (HTML) Get PDF (354K)